Assays to measure homologous recombination deficiency (HRD) in ovarian cancer vary widely, underscoring the need for standardization, since inconsistent assay results can influence treatment decisions ...

Hematuria may occur in up to 10% of the general population and results in costly evaluation to ensure it is of no consequence, i.e., no bladder cancer (BCa) is present since hematuria is typically the ...

We spoke with Scott Jones, PhD, SVP & CSO at BioBridge Global (BBG) to understand the challenges of product-specific potency ...

The Center for Molecular Oncology at NYU Langone Health's Perlmutter Cancer Center will soon launch a new protocol for patients diagnosed with early-stage and advanced cancers, developing new ...

Persistent outcome disparities, particularly worse prognoses for Black women with breast cancer, persist even within the same genomic risk categories. Effective management requires integrating genomic ...

Allogene Therapeutics has announced an expanded collaboration with Foresight Diagnostics to develop a minimal residual disease (MRD) assay as a companion diagnostic tool for identifying patients with ...

The firm has developed a whole-blood mRNA test intended for use as a screening tool in women at elevated risk of breast cancer.

Please provide your email address to receive an email when new articles are posted on . The CNSide assay aims to help clinicians with early diagnosis, treatment plans for those with CNS cancers. The ...

(RTTNews) - Akoya Biosciences, Inc. (AKYA), Thursday announced the launch of a new multiplex immunofluorescence or mIF assay to advance antibody-drug conjugate or ADC development in breast cancer, ...

Scientists at St. Jude Children's Research Hospital have revealed previously unappreciated roles for the retrotransposon LINE ...